AJAbhijeet R. Joshi

Abhijeet R. Joshi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abhijeet R. Joshi has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Helmar Christoph Lehmann

    Universitätsklinikum Köln

    7 shared publications
  • Ilja Bobylev

    Department of Neurology, University Hospital Cologne, Cologne, Germany

    6 shared publications
  • Aaditi Karnik

    Metabolic Disorders and Neuroscience Research Lab, Department of Pharmacy, Birla Institute of Technology and Sciences, Pilani-Hyderabad Campus, Hyderabad, India

    3 shared publications
  • Christian Ritter

    Department of Neurology, University Hospital Cologne, Cologne, Germany

    3 shared publications
  • Mohammed Barham

    Department of Anatomy I, Medical Faculty, University of Cologne, Cologne, Germany

    2 shared publications
  • Sonam Dolma

    Metabolic Disorders and Neuroscience Research Lab, Department of Pharmacy, Birla Institute of Technology and Sciences, Pilani-Hyderabad Campus, Hyderabad, India

    2 shared publications

Latest Publications

  • Preclinical Pharmacokinetic and Pharmacological Profiling of B339, a Novel SARM1 Inhibitor for the Treatment of Vincristine-induced Peripheral Neuropathy

    by Aaditi Karnik, Girish Siddanagouda Hosmani, Sonam Dolma, Aditi Gangopadhyay, Amit Lalwani, Ramesh Babu Boga, D. Sriram, Punna Rao Ravi, Abhijeet R. Joshi

  • Secretase-Related Interventions in Alzheimer's

    by Aaditi Karnik, Abhijeet Joshi

    Alzheimer's disease (AD) is a common geriatric neurodegenerative disorder that develops gradually and progresses to irreversible cognitive decline. The major factors predisposing to the disease pathology include amyloid beta (Aβ) plaques and the fibrillated tangles. Aβ is connected to several cellular enzymes such as secretases, endopeptidases, and matrix metalloproteinases. α-secretase participates in the non-amyloidogenic pathway while β-secretase is the rate-limiting enzyme involved in the amyloidogenic pathway. γ-Secretase causes aberrant APP cleavage, resulting in the generation of neurotoxic Aβ peptides. Several pieces of evidence highlight the utility of agents targeting the γ-secretase as lead interventions for AD. One logical approach involves inhibiting the γ-secretase so as to minimize toxic Aβ generation. On account of the toxicities associated with γ-secretase inhibitors, another strategy involves the usage of γ-secretase modulators that produce fewer side effects. Severe toxicities associated with the synthetic γ-secretase targeting agents have now driven attention towards the search for relatively safer natural compounds as an alternative to the chemically known agents. This chapter focuses on the potential γ-secretase inhibitors, modulators, and natural compounds as emerging interventions for AD.

  • Bridging the gap: Extracellular matrix‐based strategies for peripheral nerve regeneration and neuropathic pain management

    by Siddharth Raj, Abhijeet R. Joshi

    Peripheral neuropathic pain, arising from peripheral nerve injuries, remains a significant clinical challenge because of complex pathophysiology and limited treatment options. Conventional treatments primarily provide symptomatic relief, failing to address underlying nerve damage. The extracellular matrix (ECM) plays a vital role in nerve regeneration by offering structural support and biochemical signals that regulate Schwann cell behaviour, axonal growth and microenvironment remodelling. This review critically examines ECM‐based scaffold strategies, focussing on natural proteins such as collagen, laminin and fibronectin and their role in promoting functional nerve recovery. In addition, the role of emerging molecular regulators, including Piezo1 mechanosensitive channels and nuclear transport proteins, is examined for their ability to mediate mechanotransduction and gene regulatory mechanisms critical for nerve regeneration and pain modulation. By integrating biomaterial engineering, mechanical signalling pathways and gene‐targeted strategies, this review outlines promising regenerative approaches aimed at restoring nerve function and alleviating chronic pain. These insights may guide the development of next‐generation therapies for peripheral nerve repair.


  • SARM1: The Checkpoint of Axonal Degeneration in the Nervous System Disorders

    by Aaditi Karnik, Abhijeet Joshi

    Axons are metabolically active neuronal segments with well-controlled axonal degeneration and regeneration. External stress or injury displaces this equilibrium toward degeneration leading to axonal dysfunction observed in the pathology of several diseases. The demand and supply matrix of energy at the synapses are maintained by the axonal transport. Nicotinamide adenine dinucleotide (NAD+) is a major energy-driving coenzyme of cells that controls mitochondrial, cytoplasmic, and other organellar energy cycles generating high amounts of adenosine triphosphate (ATP). NAD+ participates in various cellular cycles and is consumed by several enzymes. One of the key enzymes targeting NAD+ is Sterile alpha and TIR motif-containing protein 1 (SARM1) which gets activated in response to external noxious stimuli. SARM1 is an octamer consisting of multiple domains of which the TIR domain governs NAD+ hydrolysis which eventually leads to axonal deficits. Besides its localization in neurons, SARM1 is also present in astrocytes, microglia, and macrophages in which it regulates inflammatory responses associated with disease pathology. SARM1 localization in the outer mitochondrial membrane is responsible for its association with mitochondrial dynamics. SARM1-mediated mitochondrial dysfunction further drives the axonal degeneration associated with peripheral and central nervous system disorders. Several genetic and pharmacological studies highlight the role of SARM1 in axonal degeneration. SARM1 is thus becoming a popular target for preventing axonal degeneration. Several small molecules consisting of isoquinoline, isothiazole, pyridine, and tryptoline acrylamide moieties have been tested for their activity against SARM1 with a promising foundation for drug discovery in targeting SARM1. In our review, we highlight the role of SARM1 in axonal degeneration associated with several disease pathologies focusing on genetic and pharmacological evaluation.


  • The Node of Ranvier as an Interface for Axo-Glial Interactions: Perturbation of Axo-Glial Interactions in Various Neurological Disorders

    by Sonam Dolma, Abhijeet Joshi

    The action potential conduction along the axon is highly dependent on the healthy interactions between the axon and myelin-producing glial cells. Myelin, which facilitates action potential, is the protective insulation around the axon formed by Schwann cells and oligodendrocytes in the peripheral (PNS) and central nervous system (CNS), respectively. Myelin is a continuous structure with intermittent gaps called nodes of Ranvier, which are the sites enriched with ion channels, transmembrane, scaffolding, and cytoskeletal proteins. Decades-long extensive research has identified a comprehensive proteome with strictly regularized localization at the node of Ranvier. Concurrently, axon-glia interactions at the node of Ranvier have gathered significant attention as the pathophysiological targets for various neurodegenerative disorders. Numerous studies have shown the alterations in the axon-glia interactions culminating in neurological diseases. In this review, we have provided an update on the molecular composition of the node of Ranvier. Further, we have discussed in detail the consequences of disruption of axon-glia interactions during the pathogenesis of various CNS and PNS disorders. Graphical Abstract


  • Impact of Age and Polytherapy on Fingolimod Induced Bradycardia: a Preclinical Study

    by Christian Ritter, Martin K. R. Svačina, Ilja Bobylev, Abhijeet Joshi, Toni Schneider, Helmar C. Lehmann

    Fingolimod is a an oral disease modifying drug for relapsing remitting multiple sclerosis (MS) preventing egress of B and T cells from lymph nodes. Relevant first dose adverse events include bradycardia and atrioventricular conduction slowing. Cardiac side effects of fingolimod and combinational pharmacotherapy including duloxetine and tolterodine were monitored in mice of different age using implantable ECG telemetric systems. Cardiac tissue was assessed for S1P-receptor subtype (1 and 3), and for GIRK1 expression. Fingolimod led to a significant heart rate reduction within 60 min, which returned to baseline values within 24 h. In older mice bradycardia was more pronounced compared to younger mice. Atrioventricular conduction was not affected. Older mice showed a higher S1PR3 expression in a naïve state and receptor expression was reduced after fingolimod administration. Combination with duloxetine or tolterodine alleviated fingolimod induced heart rate decrease. Our data provide preclinical evidence that negative chronotropic effects of fingolimod might be age dependent, possibly due to an altered expression and internalization of cardiac S1PR3 in older animals. This data could be relevant for future clinical monitoring and patient selection in the aging MS population. Combinational therapies of fingolimod and duloxetine or tolterodine are well tolerated and safe without an increased risk for pronounced bradycardia or arrhythmia.


  • Depletion of Mitofusin-2 Causes Mitochondrial Damage in Cisplatin-Induced Neuropathy

    by Ilja Bobylev, Abhijeet R. Joshi, Mohammed Barham, Wolfram F. Neiss, Helmar C. Lehmann

    Sensory neuropathy is a relevant side effect of the antineoplastic agent cisplatin. Mitochondrial damage is assumed to play a critical role in cisplatin-induced peripheral neuropathy, but the pathomechanisms underlying cisplatin-induced mitotoxicity and neurodegeneration are incompletely understood. In an animal model of cisplatin-induced neuropathy, we determined in detail the extent and spatial distribution of mitochondrial damage during cisplatin treatment. Changes in the total number of axonal mitochondria during cisplatin treatment were assessed in intercostal nerves from transgenic mice that express cyan fluorescent protein. Further, we explored the impact of cisplatin on the expression of nuclear encoded molecules of mitochondrial fusion and fission, including mitofusin-2 (MFN2), optic atrophy 1 (OPA1), and dynamin-related protein 1 (DRP1). Cisplatin treatment resulted in a loss of total mitochondrial mass in axons and in an abnormal mitochondrial morphology including atypical enlargement, increased vacuolization, and loss of cristae. These changes were observed in distal and proximal nerve segments and were more prominent in axons than in Schwann cells. Transcripts of fusion and fission proteins were reduced in distal nerve segments. Significant reduced expression levels of the fusion protein MFN2 was detected in nerves of cisplatin-exposed animals. In summary, we provide for the first time an evidence that cisplatin alters mitochondrial dynamics in peripheral nerves. Loss of MFN2, previously implicated in the pathogenesis of other neurodegenerative diseases, also contributes to the pathogenesis in cisplatin-induced neuropathy.


  • Open Access

    Loss of Schwann cell plasticity in chronic inflammatory demyelinating polyneuropathy (CIDP)

    by Abhijeet R. Joshi, Laura Holtmann, Ilja Bobylev, Christian Schneider, Christian Ritter, Joachim Weis, Helmar C. Lehmann

    Chronic inflammatory demyelinating polyneuropathy (CIDP) is often associated with chronic disability, which can be accounted to incomplete regeneration of injured axons. We hypothesized that Schwann cell support for regenerating axons may be altered in CIDP, which may account for the poor clinical recovery seen in many patients. We exposed human and rodent Schwann cells to sera from CIDP patients and controls. In a model of chronic nerve denervation, we transplanted these conditioned Schwann cells intraneurally and assessed their capacity to support axonal regeneration by electrophysiology and morphometry. CIDP-conditioned Schwann cells were less growth supportive for regenerating axons as compared to Schwann cells exposed to control sera. The loss of Schwann cell support was associated with lower levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) in CIDP sera and correlated with altered expression of c-Jun and p57kip2 in Schwann cells. The inactivation of these regulatory factors resulted in an altered expression of neurotrophins including BDNF, GDNF, and NGF in CIDP-conditioned Schwann cells in vitro. Our study provides evidence that pro-regenerative functions of Schwann cells are affected in CIDP. It thereby offers a possible explanation for the clinical observation that in many CIDP patients recovery is incomplete despite sufficient immunosuppressive treatment.


  • Toxicity to sensory neurons and Schwann cells in experimental linezolid-induced peripheral neuropathy

    by Ilja Bobylev, Helina Maru, Abhijeet R. Joshi, Helmar C. Lehmann

    Objectives Peripheral neuropathy is a common side effect of prolonged treatment with linezolid. This study aimed to explore injurious effects of linezolid on cells of the peripheral nervous system and to establish in vivo and in vitro models of linezolid-induced peripheral neuropathy. Methods C57BL/6 mice were treated with linezolid or vehicle over a total period of 4 weeks. Animals were monitored by weight, nerve conduction studies and behavioural tests. Neuropathic changes were assessed by morphometry on sciatic nerves and epidermal nerve fibre density in skin sections. Rodent sensory neuron and Schwann cell cultures were exposed to linezolid in vitro and assessed for mitochondrial dysfunction. Results Prolonged treatment with linezolid induced a mild, predominantly small sensory fibre neuropathy in vivo. Exposure of Schwann cells and sensory neurons to linezolid in vitro caused mitochondrial dysfunction primarily in neurons (and less prominently in Schwann cells). Sensory axonopathy could be partially prevented by co-administration of the Na+/Ca2+ exchanger blocker KB-R7943. Conclusions Clinical and pathological features of linezolid-induced peripheral neuropathy can be replicated in in vivo and in vitro models. Mitochondrial dysfunction may contribute to the axonal damage to sensory neurons that occurs after linezolid exposure.